| Preface |
|
vii | |
| Acknowledgment |
|
viii | |
| Contributors |
|
ix | |
|
Fever and neutropenia: An historical perspective |
|
|
1 | (26) |
|
|
|
|
|
|
Overview of pharmacokinetic and pharmacodynamic principles of anti-infective dosing in the neutropenic patient |
|
|
27 | (18) |
|
|
|
|
|
|
|
|
|
|
|
Controversies and quandaries: The design of clinical trials in fever and neutropenia |
|
|
45 | (12) |
|
|
|
|
|
|
|
|
|
|
|
Current epidemiology of infections in neutropenic cancer patients |
|
|
57 | (34) |
|
|
|
|
|
|
Infections in patients with solid tumors |
|
|
91 | (20) |
|
|
|
|
|
|
Infections in patients with hematologic malignancies |
|
|
111 | (14) |
|
|
|
|
|
|
Evaluation and management of fever in the neutropenic hematopoietic stem cell transplant patient |
|
|
125 | (26) |
|
|
|
|
|
|
Initial clinical evaluation and risk assessment of the febrile neutropenic cancer patient |
|
|
151 | (16) |
|
|
|
|
|
|
|
|
|
|
|
Risk-adjusted management of the febrile neutropenic cancer patient |
|
|
167 | (22) |
|
|
|
|
|
|
|
|
|
|
|
Evaluation and management of vascular access device infections in febrile neutropenic cancer patients |
|
|
189 | (12) |
|
|
|
|
|
|
|
|
|
|
|
Special considerations in children with fever and neutropenia |
|
|
201 | (14) |
|
|
|
|
|
|
|
|
|
|
|
Prophylaxis of infections |
|
|
215 | (30) |
|
|
|
|
|
|
Cytokines and WBC transfusions |
|
|
245 | (46) |
|
|
|
|
|
|
|
|
|
|
|
Clinical practical guidelines in patients with fever and neutropenia |
|
|
291 | (10) |
|
|
|
|
|
|
|
|
|
|
|
Healthcare economic concepts in fever and neutropenia |
|
|
301 | (16) |
|
|
|
|
|
|
Fever in the neutropenic patient: Past lessons and future prospects |
|
|
317 | (6) |
|
|
|
|
|
| Index |
|
323 | |
Shopping Cart
